Aytu BioPharma Inc (AYTU) reports a mixed quarter with decreased revenues but a promising start for its novel depression treatment, EXXUA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results